Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced the phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival or progression-free survival in patients with platinum-resistant or -refractory ovarian cancer.
Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.
Cardiovascular toxicities seen early in treatment with immune checkpoint inhibitors
Gradalis Inc. presented initial data from its phase II trial for Ewing's sarcoma at the 2018 Annual Meeting of Children's Oncology Group.
Merck announced the phase III KEYNOTE-181 trial investigating Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has met a primary endpoint of overall survival in patients whose tumors expressed PD-L1 (Combined Positive Score ≥10).
Zymeworks Inc., announced the plenary presentation of updated ZW25 clinical data by Murali Beeram, a clinical investigator at the START Center for Cancer Care in San Antonio.
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women, led in the UK by Queen Mary University of London.
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors.
Pfizer Inc. announced the introduction of Retacrit (epoetin alfa-epbx) injection, the first available biosimilar to Procrit (epoetin alfa) and Epogen (epoetin alfa) in the U.S, at a substantial discount.
TESARO Inc. presented initial data from the phase I AMBER trial of TSR-022 (anti-TIM-3 antibody) in combination with TSR-042 (anti-PD-1 antibody) in patients who have progressed following anti-PD-1 therapy treatment, in an oral session during the 2018 Annual Meeting of the Society for Immunotherapy of Cancer Conference in Washington, D.C.
